We have shown that aggressive lipid lowering by pitavastatin and atorvastatin results in marked regression of atherosclerotic coronary lesions after acute coronary syndrome (ACS). The purpose of this study was to address the association of lipid levels after statin therapy with regression of atherosclerotic coronary lesions and major cardiovascular events in patients after ACS. Methods: JAPAN-ACS is a prospective, randomized open-label study performed at 33 centers in Japan. Patients with ACS undergoing intravascular ultrasound (IVUS)-guided percutaneous coronary intervention (PCI) were randomly assigned to receive either 4 mg/day pitavastatin or 20 mg/day atorvastatin within 72 hours after PCI. IVUS image was obtained in 251 patients, including 73 diabetic patients. Lipid profiles at the end of the study were divided into quartiles and the association with the percent change in non-culprit coronary plaque volume (PV) was assessed in total and diabetic patients. We also studied whether baseline and follow-up levels of HDL-cholesterol are associated with restenosis after PCI. Results: Decreasing LDL-cholesterol, non-HDL-cholesterol, LDL-C/HDL-C ratio, apolipoprotein B quartiles were associated with a progressively smaller plaque burden in total and diabetic patients. In diabetic patients, further reduction of these parameters was associated with a significantly greater reduction in PV. We also found that patients with lower HDL-cholesterol had a significantly higher incidence of target lesion revascularization. Conclusions: Early intensive statin therapy in patients after ACS results in remarkable regression of coronary PV. Diabetic patients can have a benefit with more intensive therapy to achieve a lower target level in Japanese.
Introduction
Accumulating evidence indicates that statins can reduce both cardiovascular morbidity and mortality in primary and secondary prevention, including patients study, as the regressive effect of the two statins was shown to be equivalent.
In this study we also asked whether baseline and follow-up levels of HDL-cholesterol are associated with restenosis or other cardiovascular events after PCI to show the effect of low HDL-cholesterolemia on coronary events, because previous studies have shown that low levels of HDL-cholesterol can predict major cardiovascular events [11] [12] [13] .
Methods

Study Design
The present study is a post-hoc sub-analysis of the JAPAN-ACS (Japan Assessment of Pitavastatin and Atorvastatin in Acute Coronary Syndrome) study. JAPAN-ACS is a prospective, randomized open-label parallel group study with blind endpoint evaluation at 33 centers to examine the effect of 8 − 12 months treatment with pitavastatin versus atorvastatin in coronary plaque regression in non-percutaneous coronary intervention (PCI) sites of the culprit vessel in patients with ACS. The details of the study design have been reported previously 9, 14) . In brief, ACS patients selected in this study were over 20 years of age with hypercholesterolemia and had undergone successful PCI under IVUS guidance. They were found to have coronary plaques (more than 500 m in thickness, or percent plaque area ≥ 20%) in the culprit vessel at least 5 mm from the PCI-treated lesions. ACS was defined as unstable angina pectoris, non-ST-elevation myocardial infarction (MI) or ST-elevation MI. The diagnosis of ACS was made based on the fulfillment of at least two of the following three criteria: 1) evidence of coronary ischemia on ECG, 2) increase ( ≥ 2 times) in the serum creatinine phosphokinase (CK) or CK-MB levels, and/or troponin-T positivity, 3) presence of symptoms suggestive of ACS. Diabetes mellitus and other complications were diagnosed by the attending physicians. This study was conducted according to the 'Declaration of Helsinki', and with the approval of the institutional review boards of all 33 participating institutions. Written informed consent to participate was obtained from all of the patients enrolled.
Intravascular Ultrasound Procedure and Examination
Details of the intravascular ultrasound (IVUS) procedure and examination are documented elsewhere 9) . In brief, following IVUS-guided PCI for the culprit lesion in the patients with ACS, a final IVUS examination for analysis was performed in the culprit vessel. The IVUS catheter Atlantis SR Pro2 (Boston with acute coronary syndrome (ACS) [1] [2] [3] . Lowering LDL-cholesterol to even lower levels is associated with a further reduction in cardiovascular risk, as shown in the Treatment to New Target (TNT) Study 4) and in the Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study of secondary prevention 5) . These studies support the hypothesis that a lower LDL-cholesterol level can induce a greater risk reduction, at least in secondary prevention.
Moreover, many studies with surrogate endpoints show improvement of atherosclerosis by aggressively lowering LDL-cholesterol. Studies using intravascular ultrasound (IVUS) imaging demonstrate that statins attenuate the progression of atherosclerosis or even enable regression of atheromatous plaque 6, 7) . An IVUS study of patients with ACS also demonstrated that atorvastatin can reduce non-culprit coronary plaque in Japanese 8) ; however, this was a relatively small trial conducted at a single center. Therefore, a larger multicenter study is expected to address the further roles of statins in patients with ACS.
We previously reported the results of the JAPAN-ACS (Japan Assessment of Pitavastatin and Atorvastatin in Acute Coronary Syndrome) study to address the role of statins in patients with ACS 9) . The JAPAN-ACS was performed as a prospective, randomized open-label parallel-group study with a blind endpoint evaluation at 33 centers, to comparatively examine the effect of 8-to 12-month treatment with pitavastatin and atorvastatin on the degree of coronary plaque regression in non-culprit lesions of the culprit vessel treated by PCI in patients with ACS. This study demonstrated the non-inferiority of pitavastatin 4 mg/day to atorvastatin 20 mg/day, with approximately 17% regression of the plaque volume (PV), suggesting that the effect of inducing plaque regression can be generalized to other statins with similar LDL-lowering effects with atorvastatin. However, in this study, diabetic patients showed less regression of coronary atheroma than non-diabetic patients in spite of similar LDL-cholesterol reduction by statins. In the sub-analysis of JAPAN-ACS we showed significant correlations between the percent change in PV and percent change of the LDL-cholesterol level or follow-up LDL-cholesterol level in diabetic patients 10) ; however, a question remains whether there is an appropriate target lipid level to obtain the maximum effect on plaque regression. Therefore, in this sub-analysis of JAPAN-ACS we examined the association of lipid levels after statin therapy with the regression of atherosclerotic coronary lesions in diabetic and total patients after ACS. This analysis was performed in the entire patient population, using the full analysis set of the JAPAN-ACS Scientific, Natik, USA) was used, and a motorized pullback device withdrew the transducer at 0.5 mm/sec. The consoles used were the ClearView or Galaxy 2 system (Boston Scientific, Natik, USA). The same imaging system with the same type of IVUS catheter was used for both the baseline and follow-up examinations Two independent experienced investigators performed the quantitative IVUS analysis at the central laboratory. The target segment for analysis was identified as a non-PCI site of the culprit vessel ( 5 mm proximal or distal to the PCI site) based on reproducible indices. Manual tracing was performed in every 0.1 mm cross-section and the software (echoPlaque2; INDEC systems Inc., Santa Clara, USA) automatically interpolated the tracings of 5 cross-sections between two manually traced images; therefore, the volume was calculated from each of the 0.017 mm-interval segments.
Blood Examination
Blood examinations for lipid levels were performed at baseline and 8 − 12 months follow-up. Lipid profiles were measured at SRL Co, Ltd. (Tokyo, Japan).
Statistical Analysis
We used the full analysis set (FAS) of data for primary analyses. Patient data were included in FAS if patients had ACS and measurable IVUS both at enrollment and follow-up. Because non-inferiority was shown between pitavastatin and atorvastatin, we combined the data of both groups and performed this subanalysis. LDL-cholesterol, non-HDL-cholesterol, LDL-C/HDL-C ratio, and apolipoprotein B (apo B) at the end of the study were divided into quartiles and the percentage change in PV in each quartile was compared in total and diabetic patients by ANOVA or t test when appropriate. The chi-square test was used for categorical variables. We also analyzed the association of baseline and follow-up HDL-cholesterol (over or equal to 40 mg/dL or less than 40 mg/dL) with the rate of restenosis in this cohort. The significance level was 5% two-sided (2.5% one-sided) and all statistical analyses were performed using the SAS System Release 9.1 (SAS institute, Cary, USA).
Results
Patient Population
The characterstics of patients in the present study are shown in The details of baseline demographics and characteristics in this study have been reported elsewhere 9) . Among 251 total cohorts, 73 patients were diabetic. There were no differences in the percent change of PV and LDL-cholesterol reduction between pitavastatin and atorvastatin groups in patients with or without diabetes. In diabetic patients, the percent change of PV was 13. Table 1 shows 25th and 75th percentiles and medians in each lipid parameter in total and diabetic populations. According to these numbers we divided the total and diabetic patients into quartiles and compared the percent change of PV in each group ( Table 2) . Decreasing LDL-cholesterol, non-HDL-cholesterol, apo B, and LDL-C/HDL-C ratio quartiles were associated with a progressively larger percent change of PV in total and diabetic patients. The difference was significant in all parameters of the total cohort, while the difference was significant only in apo B and LDL-C/ HDL-C in diabetic patients. We also analyzed baseline demographics of each quartile according to follow-up LDL-cholesterol ( Table 3 ). The mean age and the prevalence of alcohol drinkers were higher in the first quartile than the other quartiles, which might affect less PV change in the first quartile. Total cholesterol, LDL-cholesterol, non-HDL-cholesterol, apo B, and apo B/apo AI were higher in the third and fourth quartiles than the others. Because we noticed a smaller percent change of PV in the fourth quartile than the others, we compared the percent change of PV between the combined data from the first to third quartiles and the fourth quartile in each lipid parameter (Fig. 2) . There was a significant difference between the two groups by t test in all the lipid parameters, indicating that the fourth quartile had less plaque regression than the others.
Association of Percent Change in Plaque Volume with Quartiles of Lipid Parameters
Next, we compared the percent change of PV in diabetic patients. The baseline characteristics of diabetic patients according to the quartiles of follow-up LDL are shown in Table 4 . There was no significant difference in age, sex, BMI, waist circumference, or the prevalence of hypertension, family history of coronary artery disease, smoking, and alcohol drinking in this cohort, while total cholesterol, LDL-cholesterol, non-HDL-cholesterol, LDL-C/HDL-C ratio, apo B, apo B/apo AI ratio were higher in the third and fourth quartiles than the others. When we performed the same analysis with the total cohort, a significant difference was found between the combined data from the first to third quartiles and the fourth quartile, except non-HDL-cholesterol ( Fig. 3) . Because further reduction of lipid profiles seemed to result in further reduction of PV in diabetic patients, we also compared the percent PV change after dividing them into 2 groups according to the median. As shown in Fig. 4 , a significant difference was found between the two groups, except in non-HDL-cholesterol. However, the p value was smaller in LDL-cholesterol when we used the median as a cutoff value, while it was larger in apo B. Although we did not find significant differences in non-HDL-cholesterol, a p value of 0.028 was obtained when we used a cutoff of 100 mg/dL for non HDLcholesterol.
Effect of HDL-Cholesterol Levels on Major Adverse Cardiovascular Events
To examine the effect of HDL-cholesterol levels on major adverse cardiovascular events (MACE), such as target lesion revascularization (TLR) and target vessel revascularization (TVR), we compared their incidence in the total cohort according to baseline and follow-up HDL-cholesterol levels ( ≥ 40 mg/dL or 40 mg/dL). As shown in Table 5 , patients with lower HDL-cholesterol at baseline or follow-up showed a significantly higher incidence of TLR, but not of TVR or other vessel revascularization. The baseline characteristics of the two groups according to the levels of follow-up HDL-cholesterol levels are shown in Table 6 . There was no significant difference in demographic characteristics between the two groups. As expected, HDL-cholesterol and apo AI were higher and the LDL-C/HDL-C ratio and apo B/AI were lower in patients with higher HDL-cholesterol. A similar finding was observed when we divided the patients according to baseline HDL-cholesterol levels (data not shown).
Discussion
In this post-hoc analysis of the JAPAN-ACS study we have shown that diabetic patients had more regression by targeting lower levels of LDL, non-HDL cholesterol, and LDL-C/HDL-C with intensive lipidlowering therapy in Japanese; however, our data may indicate that the same target can be used for apo B in diabetic or non-diabetic ACS patients. We also found that patients with lower HDL-cholesterol had a higher risk for target lesion revascularization, and should be considered for additional therapy to prevent restenosis.
IVUS provides a precise evaluation of the vascular wall and has been shown to be the most sensitive and reliable technique for measuring coronary atherosclerosis progression and regression 15) . Several IVUS trials have shown that intensive lipid-lowering therapy is associated with a decrease of atherosclerosis progression or regression of plaque burden 6) . In the JAPAN-ACS we found much more regression of coronary atheroma after statin therapy than these studies in US 6, 7) . Consistent with our findings, Okazaki et al. also showed similar regression with 20 mg atorvastatin after ACS 8) . These data may indicate that Japanese patients are more susceptible to statin therapy in terms of atheroma regression; however, Takayama et al. have recently shown that rosuvastatin can induce significant regression of coronary PV ( 5.1%) in Japanese patients with stable CAD 16) , consistent with the find-ings by Nissen et al. 6, 7) . Taken together, the differences in regression rates between ours and those of Nissen et al. might be derived from the patient population; stable CAD and ACS patients. It is still difficult to investigate non-culprit coronary arteries by IVUS in Japan, which might also explain the difference between Japanese and US studies.
The National Cholesterol Education Program currently recommends an optional target LDL-cholesterol of 70 mg/dL for patients at high risk of cardiovascular events, including those with an ACS event 17) , while the Japanese guideline recommends an LDLcholesterol target 100 mg/dL for secondary prevention 18) . However, this study might provide a rationale for more aggressive lipid lowering, targeting LDL-cholesterol of 75 or 70 mg/dL in diabetic patients after ACS, while non-diabetic patients can be treated to reach LDL-cholesterol of 100 mg/dL. Our data also support non-HDL-cholesterol as an additional target for the management of ACS patients. Although the median cutoff did not result in a significant difference, a significant difference was observed when we used 100 mg/dL for the cutoff, which is consistent with the guidelines of the National Cholesterol Education Program for very high-risk patients. In terms of apo B, we obtained a smaller p value when we used a cutoff of 88 mg/dL than 70 mg/L in diabetic patients, which was almost the same in the total cohort. We showed less regression of coronary atheroma in diabetic patients after intensive statin treatment even though the mean LDL-cholesterol levels were almost the same in diabetic and non-diabetic patients. Considering that diabetic patients tend to have small dense LDL, the data on apo B might indicate that LDL particle number should be reduced to a certain level to obtain the maximum effects for plaque regression in diabetic patients. Further study is required to develop a rationale for aggressive lipid-lowering therapy in Japanese.
In this sub-analysis, we showed that low HDLcholesterolemia 40 mg/dL was associated with increased TLR after ACS. As shown in Table 6 , there was no demographic difference between the two groups except apo A1 and the ratio of LDL to HDL-cholesterol and the apo B to apo A1 ratio, indicating that low levels of HDL-cholesterol are a powerful predictor of major cardiovascular events even in patients treated with the maximum dose of statins. Previous studies have also shown that HDL-cholesterol levels during statin treatment are independently predictive of major cardiovascular events even in patients with LDL-cholesterol levels less than 70 mg/dL 11, 12) . Recently, Taylor et al. have shown that the use of extended-release niacin causes significant regression of carotid intimamedia thickness when combined with a statin 19) ; therefore, additional treatment might be required to raise HDL-cholesterol to prevent major cardiovascular events in patients with low HDL-cholesterolemia.
The current study has some limitations. The first is that LDL-cholesterol was determined by a direct method, not by a Friedwald equation because the equation could not be applied for blood samples from some patients. Recently, Nakamura et al. have shown that the direct measurement of LDL-cholesterol is still poor in terms of accuracy and stability 20) ; however, even when we used the equation, we found similar results with this analysis (data not shown). The second is that this study lacked a control group receiving a placebo or less-intensive lipid-lowering therapy because the JAPAN-ACS study was designed to prove the non-inferiority of pitavastatin against atorvastatin.
In this sub-analysis we combined the data on both statins; however, we deemed it ethically unacceptable to give a placebo to patients with ACS. The third is that the diagnosis of diabetes mellitus was made by the attending physicians, and no oral glucose tolerance test was performed to confirm diabetes, which is why we did not analyze non-diabetic patients.
In conclusion, early intensive statin therapy in Japanese patients after ACS resulted in the marked regression of coronary PV in total and diabetic patients. Diabetic patients can obtain more benefit from intensive lipid-lowering therapy with lower target levels of LDL, non-HDL-cholesterol, and LDL-C/ HDL-C in Japanese. These lipid profiles may be related to the coronary plaque burden in statin-treated patients. On the other hand, low HDL-cholesterol levels are related to major cardiovascular events; therefore, patients with lower HDL-C are recommended for more intensive and comprehensive management to prevent the recurrence of coronary events. for IVUS core laboratory management and IVUS planimetry, and Natsuko Yamamoto for QCA core laboratory managements.
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